Perinatal EvidenceCompass
Prepopulated workbenchMED-189

Anxiolytics/symptom-targeted

Buspirone

Anxiolytic or symptom-targeted off-label psychiatric medication

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Buspirone
Entity type
single-ingredient drug
Active component(s)
Buspirone
Formulation / route / interval
Oral; formulation varies
Attachment entry
Buspirone
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Also: antidepressant augmentation
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

3 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

A-032Provisional public source

A prospective buspirone registry report observed no malformations among 72 infants, but could not exclude uncommon risks.

Public-source certainty descriptor
low; preliminary; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
first trimester
Comparator
no internal unexposed comparator
Effect or numbers carried forward

72 infants; zero malformations reported.

Limitations

Small sample and voluntary registry; insufficient for specific malformations, obstetric, neonatal, or neurodevelopmental outcomes.

Sources, citation controls, and verification state

Linked sources

PMID
35840767
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-033Provisional public source

A small buspirone lactation study found low relative infant doses and no reported infant adverse events.

Public-source certainty descriptor
low for infant safety; moderate for measured transfer; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
lactation
Comparator
no unexposed infant comparator
Effect or numbers carried forward

RID range 0.21%-2.17%.

Limitations

Small sample, short follow-up, and limited infant outcome ascertainment.

Sources, citation controls, and verification state

Linked sources

PMID
38376615
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-067Provisional public source

FDA prescription labeling uses narrative Pregnancy and Lactation Labeling Rule sections rather than the former A/B/C/D/X letter categories.

Public-source certainty descriptor
high for US regulatory framework
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and lactation
Comparator
not applicable
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Exact labeling and revision date remain product-specific; non-US systems differ.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending